BioTime wound management gel cleared for sale

The FDA approves BioTime's (BTX +3.5%) Premvia hydrogel for the management of wounds. The Class II device mimics the human body's extracellular matrix by cross-linking collagen and hyaluronic acid. It is the first member of the company's HyStem family of products to achieve regulatory clearance in the U.S.

Comments (1)
  • docrog123
    , contributor
    Comments (150) | Send Message
    Golly Gee Guys! Isn't that just buffy? And they tell me it rained in Sudan yesterday too and it surprised everyoned! Looks to me like there are two personnel changes needed. Sudan needs a new meteorologist and BTX needs a new CEO who knows what his job is and why people invested in BTX.
    13 Aug 2014, 04:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs